iC9.GD2.CAR.IL-15 T-cells

Phase 1Cell therapy

UUNC Lineberger Comprehensive Cancer Center

iC9.GD2.CAR.IL-15 T-cells is one of 74 biologic programs targeting Lung Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerActive, not recruiting

NeuroblastomaActive, not recruiting

Lung CancerPhase 1

Active, not recruiting

NeuroblastomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

686 competitors in Lung Cancer

#DrugCompanyPhaseTrials

Libtayo

Regeneron

Preclinical

3 2

Vizimpro

Pfizer

Preclinical

3 3

Talzenna

Pfizer

Preclinical

2 4

Folvite

Xylocaine

2 6

Immunotherapy

Bristol-Myers Squibb

Preclinical

5 7

Paclitaxel and Carboplatin

Bristol-Myers Squibb

Preclinical

2 8

Acupan

YYonsei University

Preclinical

—9

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

COVID-19 Vaccine

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2029

Phase 1Recruiting

Lung Cancer

NCT05620342

Q2 2044

Phase 1Recruiting

Neuroblastoma

NCT03721068

Clinical

Trials by Indication[1]

Neuroblastoma1 trial

Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma

Recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT03721068·18 enrolled

Lung Cancer1 trial

Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer

Recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 1·NCT05620342·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for iC9.GD2.CAR.IL-15 T-cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — iC9.GD2.CAR.IL-15 T-cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for iC9.GD2.CAR.IL-15 T-cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — UNC Lineberger Comprehensive Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: UUNC Lineberger Comprehensive Cancer Center

iC9.GD2.CAR.IL-15 T-cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2029

Q2 2044

Trials by Indication[1]

Neuroblastoma1 trial

Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News